Aneta Guzek | Bloodstream Infections | Best Researcher Award

Published on by World Top Scientists

Dr. Aneta Guzek | Bloodstream Infections | Best Researcher Award

Head of Microbial Laboratory | National Research Institute | Poland

Dr. Aneta Guzek is the Head of the Microbiology Laboratory at the Military Institute of Medicine – National Research Institute in Warsaw, Poland, specializing in medical microbiology and laboratory diagnostics. She holds a PhD in medicine with a specialization in medical microbiology from the Military Institute of Medicine, complemented by postgraduate qualifications in medical microbiology from the Medical University of Lublin and innovation management in the health care sector from Kozminski University. Additionally, she earned an MSc in biology with a focus on microbiology from the University of Warsaw and is a certified laboratory diagnostician. Dr. Guzek leads a multidisciplinary team overseeing comprehensive microbiological diagnostics, implementation of advanced diagnostic methods, and the development of institutional policies on infection control and antibiotic stewardship. Her research contributions include studies on antimicrobial resistance, hospital infection control, and the advancement of microbiological procedures, with numerous publications and citations in recognized scientific sources. She collaborates with national and reference laboratories, contributing to public health and medical innovation. Her exemplary service has been recognized with prestigious honors, including the first place in the Hippocrates Medical Poll for Laboratory Diagnostician of the Year and the Badge of Honour from the Military Medical Institute for her efforts during the COVID-19 pandemic. Dr. Guzek also holds certification in Good Clinical Practice (ICH E6 R2), underscoring her commitment to excellence in research and clinical integrity.

Profiles: Scopus | ORCID

Featured Publications

1. Guzek, A., et al. (2025). Microbiological comparison of maxillary sinus rinses in non-odontogenic and odontogenic sinusitis of primarily endodontic origin. Journal of Clinical Medicine.

2. Guzek, A., et al. (2024). Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland. Journal of Clinical Medicine.

3. Guzek, A., et al. (2024). Dissemination of extensively drug-resistant NDM-producing Providencia stuartii in Europe linked to patients transferred from Ukraine, March 2022 to March 2023. Eurosurveillance.

Dr. Laura Cerchia | translational cancer research | Best Researcher Award

Published on by World Top Scientists

Dr. Laura Cerchia | translational cancer research | Best Researcher Award

PI, Group Leader at Institute of Endotypes in Oncology, Metabolism and Immunology “G. Salvatore”, National Research Council, Italy

Dr. Laura Cerchia is a leading researcher in cancer-targeting RNA aptamer technologies, serving as Group Leader at the Institute of Endotypes in Oncology, Metabolism and Immunology (CNR, Italy). She pioneered the cell-SELEX method, widely adopted across international labs, and developed multiple aptamers targeting tumor biomarkers such as EGFR, AXL, and PDGFRβ. These aptamers have significant applications in imaging, immunotherapy, and targeted drug delivery, with some now used globally in advanced nanomedicine platforms. Author of over 90 peer-reviewed publications with an H-index of 36, she also holds four international patents. Dr. Cerchia has received numerous grants and serves on several national and international scientific committees, including Horizon Europe’s PHIRE project. Her expertise is recognized through roles as evaluator, editorial board member, and scientific advisor. Her work bridges fundamental research and therapeutic innovation, making her a key figure in translational oncology and a strong candidate for the Best Researcher Award.

Professional Profile 

Scopus Profile
ORCID Profile 

Education

Dr. Laura Cerchia earned her PhD in Biochemical Sciences, building a strong academic foundation in molecular biology and biochemistry. Her educational background equipped her with expertise in RNA biology, molecular diagnostics, and therapeutic development. Her advanced training allowed her to explore the structural and functional aspects of nucleic acids, which later became central to her innovative work in aptamer development. During her academic years, she developed an early interest in translational research, which led her to specialize in the design of synthetic oligonucleotides for medical applications. Her doctoral and postdoctoral studies laid the groundwork for her pioneering approach in using aptamers for targeted cancer therapy. Her education not only deepened her scientific knowledge but also instilled a critical problem-solving mindset that continues to influence her research directions. Her scholarly path reflects a combination of academic rigor and innovative thinking, forming the basis for her future contributions to biomedical science.

Professional Experience

Dr. Laura Cerchia is currently Group Leader at the Institute of Endotypes in Oncology, Metabolism and Immunology “G. Salvatore” (IEOMI) within the National Research Council of Italy (CNR). Her professional journey has been marked by impactful roles in both scientific leadership and collaborative research. She developed the widely used cell-SELEX procedure and generated several clinically relevant RNA aptamers targeting key tumor markers. Beyond laboratory research, Dr. Cerchia serves on editorial boards of journals such as Scientific Reports and Molecules, and holds evaluative and advisory roles in national and international research bodies, including the Horizon Europe-funded PHIRE project. Her career reflects a balance of scientific innovation, project management, and institutional leadership. She has successfully secured multiple research grants, built interdisciplinary teams, and advanced new diagnostic and therapeutic approaches. Her professional experience showcases her ability to lead complex research initiatives and influence the broader scientific and clinical communities.

Research Interest

Dr. Cerchia’s research focuses on the development of nuclease-resistant RNA aptamers for cancer theranostics, therapeutics, and targeted drug delivery. She is especially interested in the use of aptamers as precision tools for recognizing and binding specific biomarkers in tumors, such as EGFR, AXL, and PDGFRβ. Her work involves designing aptamers that can be used for in vitro and in vivo imaging, antagonistic therapies, and as carriers for chemotherapeutics, small molecule inhibitors, siRNAs, or photosensitizers. Her innovations in cell-SELEX have enabled the selection of highly specific aptamers against aggressive cancer types like glioblastoma, NSCLC, and triple-negative breast cancer (TNBC). She is also exploring the potential of aptamers in immunotherapy, including their integration with nanomedicine platforms. Her interest lies in translating basic molecular discoveries into clinical applications, with a strong focus on personalized medicine. Overall, her research aims to bridge gaps between molecular biology, oncology, and therapeutic delivery systems.

Award and Honor

Dr. Laura Cerchia has received multiple national and international recognitions for her contributions to cancer research and aptamer technology. She is the recipient of prestigious research grants and has been invited to serve on scientific evaluation panels, including for the Wellcome Trust (UK), ANR SHAMS, PRIN, and Horizon Europe projects. In 2018, she achieved the National Scientific Qualification, allowing her to function as a Full Professor in general and clinical pathology within Italian universities—an acknowledgment of her academic and professional excellence. She also serves as President and expert evaluator for PRIN 2022 PNRR – ERC Sector LS1, reinforcing her leadership role in shaping national research priorities. Her aptamers are cited and utilized worldwide, further validating the high translational value of her work. In addition to her editorial board positions, these honors demonstrate her broad influence, scientific credibility, and sustained contributions to advancing biomedical research on both national and international levels.

Conclusion

Dr. Laura Cerchia exemplifies the qualities of a world-class biomedical researcher through her pioneering work in RNA aptamer technologies, extensive publication record, and active leadership in the international scientific community. With a robust educational background, decades of impactful professional experience, and deep research expertise, she has made significant contributions to translational cancer therapy. Her innovations have enabled more precise targeting of tumors, enhancing both diagnostic and therapeutic capabilities. Her work has not only influenced academic circles but also spurred technological advances in nanomedicine and drug delivery. The widespread adoption of her aptamers across global research groups attests to the relevance and utility of her discoveries. Coupled with numerous awards, advisory roles, and editorial contributions, her profile reflects excellence, leadership, and a forward-looking vision in biomedical science. Dr. Cerchia’s continued efforts make her a strong candidate for high honors such as the Best Researcher Award and a role model in scientific innovation.

Publications Top Notes

  • Title: A novel therapeutic approach targeting PD-L1 in HNSCC and bone marrow-derived mesenchymal stem cells hampers pro-metastatic features in vitro: perspectives for blocking tumor-stroma communication and signaling
    Authors: Not listed
    Year: 2025

  • Title: A novel CD44-targeting aptamer recognizes chemoresistant mesenchymal stem-like TNBC cells and inhibits tumor growth
    Authors: Not listed
    Year: 2025

  • Title: Preclinical Toxicological Characterization of Porphyrin-Doped Conjugated Polymer Nanoparticles for Photodynamic Therapy
    Authors: Not listed
    Year: 2025

  • Title: Urine-Stable Aptamer-Conjugated Gold Nanorods for the Early Detection of High-Grade Bladder Cancer Residual Disease
    Authors: Not listed
    Year: 2025
    Citations: 1

  • Title: Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: implications for precision phototherapies
    Authors: Not listed
    Year: 2024
    Citations: 11

  • Title: Ferroptosis in Cancer: Epigenetic Control and Therapeutic Opportunities
    Authors: Not listed
    Year: Not available
    Citations: 6

  • Title: Subtype Transdifferentiation in Human Cancer: The Power of Tissue Plasticity in Tumor Progression
    Authors: Not listed
    Year: Not available
    Citations: 2

  • Title: Correction to: Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids
    Authors: Not listed
    Year: 2024

  • Title: Correction to: Selective Photo-Assisted Eradication of Triple-Negative Breast Cancer Cells through Aptamer Decoration of Doped Conjugated Polymer Nanoparticles
    Authors: Not listed
    Year: 2022
    Citations: 1

Olawale Ola | Veterinary Pathology | Best Researcher Award

Published on by World Top Scientists

Dr. Olawale Ola | Veterinary Pathology | Best Researcher Award

University of Ibadan, Nigeria

Olawale Olawumi Ola is a dedicated veterinary pathologist and lecturer at the University of Ibadan, Nigeria. With a passion for advancing animal health and sustainable agricultural practices, Olawale has made significant contributions to veterinary medicine, particularly in avian medicine and pathology. His research focuses on innovative vaccine development and the pathology of livestock diseases, aiming to enhance animal health management across Africa. 🌍🩺

Profile

Google Scholar

To evaluate whether Olawale Olawumi Ola is a suitable candidate for the “Best Researcher Award,” we will examine his strengths, areas for improvement, and draw a conclusion.

Strengths for the Award

  1. Academic Achievements: Olawale has a robust academic background, with multiple advanced degrees in veterinary medicine, specifically in avian medicine and anatomic pathology. His education from prestigious institutions like the University of Ibadan, a notable university in Nigeria, adds credibility to his qualifications.
  2. Publications and Research Impact: Olawale has an impressive list of publications, with numerous articles in respected journals such as the Journal of Immunoassay and Immunochemistry and Comparative Clinical Pathology. His research has addressed significant topics in veterinary pathology, including the evaluation of lung lesions, immune responses in chickens, and the development of vaccines. These contributions demonstrate his active role in advancing knowledge in his field.
  3. Professional Experience: His experience as a lecturer at multiple institutions, including the University of Ibadan, and his work as a veterinary clinician and technical sales representative, highlight his versatility and application of research in both academic and practical settings. His role in various professional capacities, including as a lecturer, clinician, and researcher, underscores his comprehensive expertise in veterinary science.
  4. Research Relevance: The focus on disease pathology and vaccine development, particularly in the context of indigenous African animal species, aligns with pressing issues in veterinary medicine and public health in Sub-Saharan Africa. This relevance to local challenges and his contribution to sustainable agriculture and animal health adds weight to his candidacy for an award focused on research impact.
  5. Innovative Contributions: The development of a microbeaded mucoadhesive Newcastle disease vaccine, particularly for oral delivery in indigenous chickens, is a notable innovation. This work shows his ability to contribute practical solutions to real-world problems, which is a significant strength in his research portfolio.

Areas for Improvement

  1. Focus on Broader Impacts: While his research is highly specialized and impactful in veterinary pathology, expanding his work to include broader interdisciplinary approaches, such as integrating environmental health or socio-economic impacts, could enhance his contributions to biodiversity conservation and sustainable agriculture.
  2. Global Collaboration: Increasing international collaboration could further elevate his research impact. While he has published extensively, partnering with global research institutions could help him gain wider recognition and potentially increase the scope and application of his work.
  3. Leadership and Mentorship: Although his academic and professional achievements are commendable, evidence of leadership in research initiatives, such as leading large-scale projects or mentoring emerging researchers, could further strengthen his profile as a top researcher.

Education:

Olawale holds an M.Sc. in Avian Medicine from the Pan African University, Ibadan, where he developed a novel microbeaded mucoadhesive Newcastle disease vaccine for indigenous Nigerian chickens. He also earned an M.V.Sc. in Anatomic Pathology and a D.V.M. from the University of Ibadan. His education has been marked by rigorous research and a commitment to improving veterinary practices. 🎓📚

Experience:

Olawale’s professional experience spans multiple roles in veterinary education and clinical practice. He currently lectures at the University of Ibadan and has previously worked as a lecturer at the Federal College of Agriculture and the School of Part-Time Studies at the Federal College of Animal Health and Production Technology. His clinical experience includes roles as a Veterinary Registrar, Clinician, and Technical Sales Representative. 🏥👨‍🏫

Research Interest:

Olawale’s research interests focus on animal pathology, vaccine development, and sustainable agriculture. He is particularly interested in developing innovative solutions to combat livestock diseases and enhance animal health through improved diagnostic and therapeutic strategies. His work aims to contribute to the broader field of biodiversity conservation in Sub-Saharan Africa. 🔬🌾

Awards:

Olawale has been recognized for his academic and research achievements with several awards, including the Pan African University Scholarship (2017) for his M.Sc. studies in Veterinary Medicine. He also received a research grant for a three-month research stay at the German-West-African Centre for Global Health and Pandemic Prevention, KNUST, Ghana, showcasing his commitment to global health initiatives. 🏆🌍

Publications:

Olawale has authored numerous research papers published in reputable journals. Some notable publications include:

Ola, O.O., Jarikre, T.A., Emikpe, B.O. (2019). “Development of Microbeaded Mucoadhesive Newcastle Disease Vaccine: Ex-Vivo and Oral Delivery Evaluation in Nigerian Indigenous Chickens.” Nigerian Veterinary Medical Association 59th National Congress Book of Abstracts. Link to article 📄

Olawale, Ola, Theophilus Jarikre, Ganiyu, Adeniran, Micheal, Odeniyi & Benjamin, Emikpe (2020). “Evaluation Of Oral Phytogenic Microbeaded Newcastle Disease Vaccine Delivery In Indigenous Chicken.” Journal of Immunoassay and Immunochemistry. DOI: 10.1080/15321819.2020.1868001 📄

Conclusion

Olawale Olawumi Ola demonstrates substantial strengths that make him a strong candidate for the “Best Researcher Award.” His significant academic background, extensive publication record, and innovative research in veterinary pathology, particularly in the development of vaccines for indigenous animals, align well with the award’s focus on impactful research. While there are areas where he could expand his influence, particularly through broader interdisciplinary work and global collaboration, his current achievements are commendable and suggest he would be a deserving recipient of the award.

His contributions to veterinary science, particularly in Sub-Saharan Africa, make him an outstanding candidate, though ongoing efforts to broaden his research impact and leadership could further solidify his standing in future award considerations.